-
公开(公告)号：US20230043835A1
公开(公告)日：2023-02-09
申请号：US17616120
申请日：2020-06-03
Applicant: Exelixis, Inc.
Inventor： Lynne Canne Bannen , Minna Bui , Faming Jiang , Kin Tso , Yong Wang , Wei Xu
IPC: C07D215/233 , C07D401/04 , C07D407/04 , C07D401/14 , C07D417/04 , C07D413/04 , C07D471/04
Abstract: Disclosed herein are compounds of Formula (I) which inhibit, regulate and/or modulate tyrosine kinase receptors, particularly Ax1 and Mer signal transduction pathways related to the changes in cellular activities, compositions containing the compounds, methods of using the compounds to treat kinase-dependent diseases and conditions, and methods for making the compounds.
-
公开(公告)号：US20210292332A1
公开(公告)日：2021-09-23
申请号：US17201380
申请日：2021-03-15
Applicant: Exelixis, Inc.
Inventor： Sunghoon Ma , Yong Wang , Wei Xu
IPC: C07D487/04 , C07D487/14 , C07D513/14
Abstract: Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein. Also disclosed herein are pharmaceutical compositions and methods of administration of heterocyclic antagonists of adenosine receptors and processes for producing heterocyclic antagonists of adenosine receptors.
-
公开(公告)号：US11124482B2
公开(公告)日：2021-09-21
申请号：US15688310
申请日：2017-08-28
Applicant: Exelixis, Inc.
Inventor： Lynne Canne Bannen , Diva Sze-Ming Chan , Jeff Chen , Lisa Esther Dalrymple , Timothy Patrick Forsyth , Tai Phat Huynh , Vasu Jammalamadaka , Richard George Khoury , James William Leahy , Morrison B. Mac , Grace Mann , Larry W. Mann , John M. Nuss , Jason Jevious Parks , Craig Stacy Takeuchi , Yong Wang , Wei Xu
IPC: C07D215/22 , C07D215/233 , A61K31/47 , A61K31/4709 , A61K31/517 , C07D295/15 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D239/88 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/5377 , C07D215/46 , C07D239/94 , C07D403/12 , C07D413/12 , C07D417/12 , C12Q1/48 , C07D215/36 , C07D215/38
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
-
公开(公告)号：US20210253530A9
公开(公告)日：2021-08-19
申请号：US15688310
申请日：2017-08-28
Applicant: Exelixis, Inc.
Inventor： Lynne Canne Bannen , Diva Sze-Ming Chan , Jeff Chen , Lisa Esther Dalrymple , Timothy Patrick Forsyth , Tai Phat Huynh , Vasu Jammalamadaka , Richard George Khoury , James William Leahy , Morrison B. Mac , Grace Mann , Larry W. Mann , John M. Nuss , Jason Jevious Parks , Craig Stacy Takeuchi , Yong Wang , Wei Xu
IPC: C07D215/233 , A61K31/496 , C07D239/94 , A61K31/4725 , C07D239/88 , C07D405/14 , A61K31/5377 , A61K31/505 , A61K31/517 , C07D295/15 , C07D413/12 , A61K31/506 , C07D401/12 , A61K31/501 , C07D413/14 , C07D215/46 , A61K31/47 , C12Q1/48 , A61K31/4709 , C07D403/12 , C07D215/22 , C07D215/36 , C07D417/12 , C07D215/38 , C07D401/14
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
-
公开(公告)号：US20140155396A1
公开(公告)日：2014-06-05
申请号：US13928977
申请日：2013-06-27
Applicant: Exelixis, Inc.
Inventor： Lynne Canne Bannen , Diva Sze-Ming Chan , Jeff Chen , Lisa Esther Dalrymple , Timothy Patrick Forsyth , Tai Phat Huynh , Vasu Jammalamadaka , Richard George Khoury , James William Leahy , Morrison B. Mac , Grace Mann , Larry W. Mann , John M. Nuss , Jason Jevious Parks , Craig Stacy Takeuchi , Yong Wang , Wei Xu
IPC: C07D215/22 , C07D401/12 , C07D239/88
CPC classification number: C07D215/233 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/5377 , C07D215/22 , C07D215/36 , C07D215/38 , C07D215/46 , C07D239/88 , C07D239/94 , C07D295/15 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C12Q1/485 , G01N2500/04 , Y02A50/393
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Abstract translation: 本发明提供调节蛋白激酶酶活性以调节细胞活性如增殖，分化，程序性细胞死亡，迁移和化学侵蚀的化合物。 更具体地，本发明提供抑制，调节和/或调节与细胞活性变化相关的激酶受体，特别是c-Met，KDF，c-Kit，flt-3和flt-4信号转导途径的喹唑啉和喹啉 如上所述，含有这些化合物的组合物，及其用于治疗激酶依赖性疾病和病症的方法。 本发明还提供了制备上述化合物的方法和含有这些化合物的组合物。
-
Patent Agency Ranking
公开(公告)号：US20240150371A1
公开(公告)日：2024-05-09
申请号：US18132124
申请日：2023-04-07
Applicant: Exelixis, Inc.
Inventor： Lynne Canne Bannen , Minna Bui , Faming Jiang , Yong Wang , Wei Xu
IPC: C07D491/147 , C07D401/12 , C07D401/14 , C07D413/14 , C07D471/04
CPC classification number: C07D491/147 , C07D401/12 , C07D401/14 , C07D413/14 , C07D471/04
Abstract: Disclosed herein are compounds of Formula I′. Compounds of Formula I′ inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
-
公开(公告)号：US20210040076A1
公开(公告)日：2021-02-11
申请号：US16964330
申请日：2019-01-25
Applicant: Exelixis, Inc.
Inventor： Lynne Canne Bannen , Minna Bui , Faming Jiang , Kin Tso , Yong Wang , Wei Xu
IPC: C07D413/12 , C07D215/22 , C07D401/12 , C07D405/12 , C07D413/10 , C07D498/04
Abstract: Disclosed herein are compounds of formula I. Compounds of formula I inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
-
公开(公告)号：US20200331860A1
公开(公告)日：2020-10-22
申请号：US16921542
申请日：2020-07-06
Applicant: Exelixis, Inc.
Inventor： Lynne Canne Bannen , Diva Sze-Ming Chan , Jeff Chen , Lisa Esther Dalrymple , Timothy Patrick Forsyth , Tai Phat Huynh , Vasu Jammalamadaka , Richard George Khoury , James William Leahy , Morrison B. Mac , Grace Mann , Larry W. Mann , John M. Nuss , Jason Jevious Parks , Craig Stacy Takeuchi , Yong Wang , Wei Xu
IPC: C07D215/233 , A61K31/47 , A61K31/4709 , A61K31/517 , C07D215/22 , C07D295/15 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D239/88 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/5377 , C07D215/46 , C07D239/94 , C07D403/12 , C07D413/12 , C07D417/12 , C12Q1/48 , C07D215/36 , C07D215/38
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
-
公开(公告)号：US20160185725A1
公开(公告)日：2016-06-30
申请号：US15066872
申请日：2016-03-10
Applicant: Exelixis, Inc.
Inventor： Lynne Canne Bannen , Diva Sze-Ming Chan , Jeff Chen , Lisa Esther Dalrymple , Timothy Patrick Forsyth , Tai Phat Huynh , Vasu Jammalamadaka , Richard George Khoury , James William Leahy , Morrison B. Mac , Grace Mann , Larry W. Mann , John M. Nuss , Jason Jevious Parks , Craig Stacy Takeuchi , Yong Wang , Wei Xu
IPC: C07D215/233 , C07D239/88 , C12Q1/48 , C07D215/36 , C07D215/38 , C07D401/12 , C07D401/14
CPC classification number: C07D215/233 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/5377 , C07D215/22 , C07D215/36 , C07D215/38 , C07D215/46 , C07D239/88 , C07D239/94 , C07D295/15 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C12Q1/485 , G01N2500/04 , Y02A50/393
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
-
公开(公告)号：US20130252940A1
公开(公告)日：2013-09-26
申请号：US13888592
申请日：2013-05-07
Applicant: Exelixis, Inc.
Inventor： Lynne Canne Bannen , Diva Sze-ming Chan , Jeff Chen , Timothy Patrick Forsyth , Tai Phat Huynh , Vasu Jammalamadaka , Richard George Khoury , James William Leahy , Morrison B. Mac , Larry W. Mann , John M. Nuss , Jason Jevious Parks , Craig Stacy Takeuchi , Yong Wang , Wei Xu
IPC: C07D215/233 , C07D413/14 , C07D401/14 , C07D405/14 , C07D295/15 , C07D401/12
CPC classification number: C07D215/233 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/5377 , C07D215/22 , C07D215/36 , C07D215/38 , C07D215/46 , C07D239/88 , C07D239/94 , C07D295/15 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C12Q1/485 , G01N2500/04 , Y02A50/393
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Abstract translation: 本发明提供调节蛋白激酶酶活性以调节细胞活性如增殖，分化，程序性细胞死亡，迁移和化学侵蚀的化合物。 更具体地，本发明提供抑制，调节和/或调节与细胞活性变化相关的激酶受体，特别是c-Met，KDF，c-Kit，flt-3和flt-4信号转导途径的喹唑啉和喹啉 如上所述，含有这些化合物的组合物，及其用于治疗激酶依赖性疾病和病症的方法。 本发明还提供了制备上述化合物的方法和含有这些化合物的组合物。
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.029 seconds)
